Skip to content
AnalystLens

United Therapeutics 8-K Report, Financial Results (Apr 30, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed April 30, 2025
Period End
April 30, 2025
Security
UTHR
In the record · 2016–202610-K1110-Q338-K152

UTHR filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 152 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Jun ’18Jun ’18
  2. Change in control8-K · Jun ’20Jun ’20
  3. Leadership change8-K · Jun ’22Jun ’22
  4. Material agreement8-K · Sep ’26Sep ’26

01—Abstract

Summary

Summary of the 8-K filed April 30, 2025. Cited figures are marked; the original filing is the authoritative source.

United Therapeutics Corporation furnished an 8-K on April 30, 2025 under Item 2.02 (Results of Operations and Financial Condition) attaching a press release (Exhibit 99.1) reporting financial results for the quarter ended March 31, 2025.

The company reported total revenues of $794.4 milliona, up 17 percent from $677.7 million in the first quarter of 2024. Net income was $322.2 million, up 5 percent from $306.6 million, and diluted earnings per share were $6.63, up 7 percent from $6.17. Growth was led by Tyvaso products, with total Tyvaso revenues rising 25 percent to $466.3 million, driven by Tyvaso DPI, which rose 33 percent to $302.5 million.

Orenitram grew 14 percent to $120.7 million and Remodulin grew 8 percent to $138.2 millionb. Operating expenses increased, with research and development expense rising 43 percent to $149.0 million, primarily due to a $30.0 million increase in milestone payments for drug delivery device technologies and a $6.6 million increase in fair value adjustments to contingent consideration for manufactured organ projects. Selling, general, and administrative expense rose 18 percent to $170.1 million, and cost of sales rose 27 percent to $92.5 million.

Operating income was $382.8 millionc, compared with $356.3 million a year earlier. Net income growth was held back by a $4.3 million other expense, net, which the company attributed primarily to net unrealized losses on equity securities, and by higher income tax expense of $101.3 million.

As of March 31, 2025, the company reported cash, cash equivalents, and marketable investments of $5,032.0 milliond, total assets of $7,743.9 million, total liabilities of $936.7 million, and stockholders' equity of $6,807.2 million. The press release also previewed the TETON 2 readout in idiopathic pulmonary fibrosis later in 2025, the planned start of a UKidney first-in-human study, and anticipated IND filings for UHeart and UThymoKidney.

02—Key points

Key Highlights

  1. Total revenues rose 17 percent year-over-year to $794.4 million, described by management as another quarter of record revenue.
  2. Tyvaso franchise revenues grew 25 percent to $466.3 million, with Tyvaso DPI up 33 percent to $302.5 million, driven by patient growth including pulmonary hypertension associated with interstitial lung disease.
  3. Net income increased 5 percent to $322.2 million; diluted EPS rose 7 percent to $6.63, aided by a lower diluted share count of 48.6 million versus 49.7 million.
  4. Research and development expense increased 43 percent to $149.0 million, largely due to $30.0 million in milestone payments for drug delivery device technologies.
  5. Operating income was $382.8 million, up from $356.3 million, while income tax expense rose to $101.3 million with an effective tax rate of 24 percent.
  6. Cash, cash equivalents, and marketable investments totaled $5,032.0 million at March 31, 2025, against stockholders' equity of $6,807.2 million.
  7. Upcoming catalysts include the TETON 2 readout in idiopathic pulmonary fibrosis, the planned UKidney first-in-human study, and anticipated IND filings for UHeart and UThymoKidney.

03—Questions

Frequently Asked Questions

  1. What were United Therapeutics' key first-quarter 2025 results?

    The company reported total revenues of $794.4 million, up 17 percent from $677.7 million, net income of $322.2 million, and diluted EPS of $6.63 compared with $6.17 in the prior-year quarter.

  2. Which products drove revenue growth?

    Tyvaso products led growth, with total Tyvaso revenues up 25 percent to $466.3 million. Tyvaso DPI revenues rose 33 percent to $302.5 million, primarily from an increase in quantities sold, and Orenitram rose 14 percent to $120.7 million.

  3. Why did research and development expense increase so sharply?

    Research and development expense rose 43 percent to $149.0 million. The filing attributes the increase mainly to a $30.0 million increase in milestone payments for drug delivery device technologies, a $6.6 million increase in fair value adjustments to contingent consideration for manufactured organ projects, and higher spending on those organ projects.

  4. Did the company's other income affect net income?

    Other (expense) income, net was an expense of $4.3 million in the first quarter of 2025, compared with income of $1.8 million a year earlier, primarily due to net unrealized losses on equity securities. Total other income, net was $40.7 million versus $42.3 million, with interest income of $51.1 million partly offset by interest expense of $6.1 million.

  5. What upcoming developments did management highlight?

    Management pointed to the readout of TETON 2 in idiopathic pulmonary fibrosis and the planned commencement of the UKidney first-in-human clinical study later in 2025, along with anticipated IND filings with the FDA for UHeart and UThymoKidney.

04—Continue

← View all 8-K filings